BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steiner S, Schwarz T, Corman VM, Sotzny F, Bauer S, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Front Immunol 2021;12:687449. [PMID: 34322120 DOI: 10.3389/fimmu.2021.687449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Kombe Kombe AJ, Biteghe FAN, Ndoutoume ZN, Jin T. CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.962079] [Reference Citation Analysis]
2 Murphy RL, Paramithiotis E, Sugden S, Chermak T, Lambert B, Montamat-sicotte D, Mattison J, Steinhubl S. The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials. Front Immunol 2022;13:923106. [DOI: 10.3389/fimmu.2022.923106] [Reference Citation Analysis]
3 Chiuppesi F, Zaia JA, Faircloth K, Johnson D, Ly M, Karpinski V, La Rosa C, Drake J, Marcia J, Acosta AM, Dempsey S, Taplitz RA, Zhou Q, Park Y, Ortega Francisco S, Kaltcheva T, Frankel PH, Rosen S, Wussow F, Dadwal S, Diamond DJ. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. iScience 2022;25:104745. [PMID: 35846380 DOI: 10.1016/j.isci.2022.104745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pothast CR, Dijkland RC, Thaler M, Hagedoorn RS, Kester MG, Wouters AK, Hiemstra PS, van Hemert MJ, Gras S, Falkenburg JF, Heemskerk MH. SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells.. [DOI: 10.1101/2022.07.31.502203] [Reference Citation Analysis]
5 Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol 2022;:e2381. [PMID: 35856385 DOI: 10.1002/rmv.2381] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
6 Maamari KA, Busaidi IA, Kindi MA, Zadjali F, BaAlawi F, Anesta W, Amri KA, Albalushi W, Balushi HA, Amri AA, Aljufaili M, Al-Busaidi M, Muharrmi ZA, Balkhair A, Riyami NA, Ghanim Z, Alshekaili J. Short and long-term immune changes in different severity groups of COVID-19 disease. Int J Infect Dis 2022:S1201-9712(22)00421-0. [PMID: 35840099 DOI: 10.1016/j.ijid.2022.07.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kilpeläinen A, Jimenez-Moyano E, Blanch-Lombarte O, Ouchi D, Peña R, Quirant-Sanchez B, Perez-Caballero R, Chamorro A, Blanco I, Martínez-Caceres E, Paredes R, Mateu L, Carrillo J, Blanco J, Brander C, Massanella M, Clotet B, Prado JG. Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Front Immunol 2022;13:815041. [PMID: 35619701 DOI: 10.3389/fimmu.2022.815041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Schwarz T, Otto C, Jones TC, Pache F, Schindler P, Niederschweiberer M, Schmidt FA, Drosten C, Corman VM, Ruprecht K. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Mult Scler 2022;:13524585221094478. [PMID: 35575234 DOI: 10.1177/13524585221094478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wirsching S, Harder L, Heymanns M, Gröndahl B, Hilbert K, Kowalzik F, Meyer C, Gehring S. Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. Front Immunol 2022;13:800070. [PMID: 35514974 DOI: 10.3389/fimmu.2022.800070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, Bošnjak B, Förster R. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Front Immunol 2022;13:863039. [PMID: 35359969 DOI: 10.3389/fimmu.2022.863039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, Gläser S, Kruse JM, Zickler D, Peric A, Meisel C, Meyer T, Staudacher OL, Wittke K, Kedor C, Bauer S, Besher NA, Kalus U, Pruß A, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Front Immunol 2022;13:840126. [PMID: 35359967 DOI: 10.3389/fimmu.2022.840126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yajima S, Yamazaki E, Shimada T, Goto A, Nakajima H, Ryo A. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.03.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Li J, Wu J, Long Q, Wu Y, Hu X, He Y, Jiang M, Li J, Zhao L, Yang S, chen X, Wang M, Zheng J, Wu F, Wu R, Ren L, Bu L, Wang H, Li K, Fu L, Zhang G, Zheng Y, Gao Z. Comprehensive humoral and cellular immune responses to SARS-CoV-2 variants in diverse Chinese populations: A benefit perspective of national vaccination.. [DOI: 10.1101/2022.02.13.22270896] [Reference Citation Analysis]
14 Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US. The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19. Front Immunol 2021;12:813300. [PMID: 35095908 DOI: 10.3389/fimmu.2021.813300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nguyen THO, Cohen CA, Rowntree LC, Bull MB, Hachim A, Kedzierska K, Valkenburg SA. T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. Front Med (Lausanne) 2021;8:793102. [PMID: 35004764 DOI: 10.3389/fmed.2021.793102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
16 Awuah A, Zamani A, Tahami F, Davis M, Grandjean L, Buckland M, Gilmour K. T cell responses to SARS-CoV-2 in healthy controls and primary immunodeficiency patients. Clin Exp Immunol 2022:uxac001. [PMID: 35020892 DOI: 10.1093/cei/uxac001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses 2022;14:79. [PMID: 35062283 DOI: 10.3390/v14010079] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 41.0] [Reference Citation Analysis]
18 Usai C, Gibbons JM, Pade C, Li W, Jacobs SR, Mcknight Á, Kennedy PTF, Gill US. The β-NGF/TrkA signalling pathway is associated with the production of anti- nucleoprotein IgG in convalescent COVID-19.. [DOI: 10.1101/2021.11.11.21266223] [Reference Citation Analysis]
19 Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K, Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S; PVI/Seronet Study Group. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell 2021;39:1442-4. [PMID: 34706273 DOI: 10.1016/j.ccell.2021.09.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 31.0] [Reference Citation Analysis]
20 Schwarz T, Otto C, Jones TC, Pache F, Schindler P, Niederschweiberer M, Schmidt FA, Drosten C, Corman VM, Ruprecht K. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.. [DOI: 10.1101/2021.10.11.21264694] [Reference Citation Analysis]